Reviews/Dry Eye Disease Treatment/Punctal occlusion improves aqueous-deficient dry eye disease
Punctal Occlusion · DED-POC-01 · v2
Across several independent studies of patients with genuinely tear-deficient dry eye, blocking the tear drainage points was consistently followed by patients reporting that their symptoms got better [1][2][4][5][7][11]. This held across different plug and surgical techniques and different countries, which is reassuring. The weakness is how the studies were run: almost all simply measured each patient before and after the procedure, with no untreated or sham group to compare against, so it is hard to rule out that some of the improvement came from expectation or natural fluctuation. The cleanest groups were also very small, and the single study that pitted plugs directly against lubricating drops found no symptom advantage for plugs [12]. The panel therefore accepted that the direction of benefit is real and reproduced, while holding back from the strongest rating because the designs cannot isolate the procedure's own effect.
Every corpus study that measured a symptom score in a confirmed aqueous-deficient population reported a statistically significant improvement after occlusion [1][2][4][5][7][11], and the effect recurs across silicone, thermosensitive and surgical methods and across multiple centres. In [7], 67% (n = 16) of 24 patients with severe ADDE reported subjective improvement, and [11] and [4] show significant symptom improvement in small surgically occluded cohorts. Supportive signals also appear in broader dry-eye populations [3][6][8]. The consistency of direction, not the strength of any single design, is what the corpus establishes. The contested point: The division is whether the improvement is specific to occlusion or partly an artefact of uncontrolled before/after measurement on a placebo-prone subjective outcome. The only head-to-head study, [12], found both plugs and artificial tears improved symptoms with no statistically significant difference between them, and states that plugs do not form tears.
All 12 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dry Eye Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Every ADDE-specific result ([1],[4],[5],[7],[11]) is a single-arm before/after series with no sham or placebo control; symptom scores are the most placebo-susceptible endpoint and are confounded by regression to the mean and the expectation effect of an in-office procedure.
The only direct comparative evidence is equivocal: [12] found no statistically significant symptom difference between plugs and artificial tears and states plugs do not form tears, undercutting a plug-specific effect.
Where it remains uncertain. The one direct comparator found no symptom advantage of plugs over artificial tears [12], and no study includes a sham control.
Aleatory
The cleanest ADDE cohorts are tiny ([11] eleven eyes of seven patients, [4] fifteen eyes of eight patients, [7] 24 eyes of 24 patients), so point estimates are imprecise and fragile to chance.
Epistemic
Almost all ADDE evidence is single-arm before/after [1][4][5][7][11]; without a sham or untreated group the procedure's own contribution to symptom change is unknown.
Inferential
Inferring that occlusion caused the improvement requires excluding regression to the mean and expectation effects, which an uncontrolled design cannot do.
The load-bearing papers from a corpus of 12, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Symptom-score improvement in a 50-patient aqueous-deficient cohort sustained to 6 months
“Our study observed a statistically significant improvement in ocular symptom scores (SPEED and OSDI scores) after punctal plugs insertion at every visit in both SS and non-SS patients (all p < 0.05).”
Panel auditInternal validity: medium · scope of inference: Sjögren and non-Sjögren aqueous-deficient dry eye patients receiving punctal plugs, followed to 6 months.Key limitations: no control group · before-after design · single centre
Explicitly ADDE population; subjective symptom relief after occlusion
“A simple, less-invasive punctal occlusion technique using a fine-needle tip with high-frequency radio-wave could significantly relieve subjective symptoms and improve ocular surface indices of patients with aqueous deficient dry eye without causing a major complication.”
Panel auditInternal validity: low · scope of inference: Aqueous-deficient dry eye refractory to conservative treatment, treated with high-frequency radiowave punctal occlusion.Key limitations: retrospective · no control · no p-value for symptom outcome · proportion-based symptom measure
Symptom improvement after surgical occlusion in ADDE (small N)
“All patients showed a statistically significant improvement of log MAR visual acuity, subjective symptoms, corneal staining (NEI score), and tear BUT.”
Panel auditInternal validity: low · scope of inference: Severe aqueous-deficient dry eye with recurrent plug loss or plug complications, undergoing surgical punctal occlusion.Key limitations: very small sample · no control · mixed secondary systemic disease · before-after design
OSDI decreased significantly from baseline in the punctal plug group (as in both groups).
Panel auditInternal validity: medium · scope of inference: Patients aged 44-74 with bilateral moderate-to-severe DED (type not specified) treated with inferior silicone plugs.Key limitations: nonrandomized · DED type not specified as aqueous-deficient · comparator is PRP not placebo · high plug loss in plug group
4 of 12 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direction of symptomatic benefit is uniform and reproduced in true ADDE populations, but uncontrolled open-label designs and an equivocal active comparator cap confidence at Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No sham-controlled trial. Every ADDE-specific result is uncontrolled before/after [1][4][5][7][11], so a placebo and regression-to-the-mean component cannot be excluded on a subjective endpoint. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised sham-controlled trial of punctal occlusion in confirmed ADDE with a validated symptom score as the primary outcome.
Open question: Does punctal occlusion improve symptoms beyond a sham procedure in confirmed aqueous-deficient dry eye? Why it is still open: No study in the corpus includes a sham or placebo control; all ADDE evidence is single-arm before/after [1][4][5][7][11].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19